These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 36231529)
1. Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients. Ordoñez-Vázquez AL; Juárez-Hernández E; Zuarth-Vázquez JM; Ramos-Ostos MH; Uribe M; Castro-Narro G; López-Méndez I Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231529 [TBL] [Abstract][Full Text] [Related]
2. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology. Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895 [TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction-associated fatty liver disease in people living with HIV. Michel M; Labenz C; Armandi A; Kaps L; Kremer WM; Galle PR; Grimm D; Sprinzl M; Schattenberg JM Sci Rep; 2023 Jun; 13(1):9158. PubMed ID: 37280241 [TBL] [Abstract][Full Text] [Related]
4. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590 [TBL] [Abstract][Full Text] [Related]
5. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359 [TBL] [Abstract][Full Text] [Related]
6. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease. McNally BB; Rangan P; Wijarnpreecha K; Fallon MB Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337 [TBL] [Abstract][Full Text] [Related]
7. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486 [TBL] [Abstract][Full Text] [Related]
8. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study. Johira Y; Nakahara T; Kinami T; Yamasaki S; Kosaka M; Shirane Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Ando Y; Kosaka Y; Kodama K; Uchikawa S; Fujino H; Ono A; Murakami E; Okamoto W; Yamauchi M; Kawaoka T; Hayes CN; Tsuge M; Imamura M; Aikata H; Oka S BMC Gastroenterol; 2023 Jun; 23(1):222. PubMed ID: 37380950 [TBL] [Abstract][Full Text] [Related]
9. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study. Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980 [TBL] [Abstract][Full Text] [Related]
10. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors. Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916 [TBL] [Abstract][Full Text] [Related]
11. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population. Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309 [TBL] [Abstract][Full Text] [Related]
12. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study. Kemp W; Clayton-Chubb D; Majeed A; Glenister KM; Magliano DJ; Lubel J; Bourke L; Simmons D; Roberts SK J Gastroenterol Hepatol; 2022 Feb; 37(2):395-403. PubMed ID: 34693553 [TBL] [Abstract][Full Text] [Related]
13. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491 [TBL] [Abstract][Full Text] [Related]
14. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort. Cheng WC; Chen HF; Cheng HC; Li CY Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531 [TBL] [Abstract][Full Text] [Related]
15. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care. Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709 [TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome. Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895 [TBL] [Abstract][Full Text] [Related]
17. Prevalence and Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease with Renal Insufficiency in Overweight/Obese Adults. Shi A; Deng J; Ma J; Yang L; Tantai X; Wang Q; Chang D; Wang J; Guo X; Lu X; Shi H Obes Facts; 2023; 16(6):548-558. PubMed ID: 37640023 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822 [TBL] [Abstract][Full Text] [Related]
20. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. Zeng J; Qin L; Jin Q; Yang RX; Ning G; Su Q; Yang Z; Fan JG Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):154-161. PubMed ID: 35153138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]